Terns Pharmaceuticals, Inc. presented updated and expanded data from the ongoing CARDINAL trial of TERN-701 at the 67th ASH Annual Meeting.
The data shows significant achievements in major molecular response rates, safety, and tolerability profiles of TERN-701 in patients with previously treated CML.
Key opinion leaders highlighted the potential of TERN-701 to be a leading therapy in treating chronic myeloid leukemia (CML) patients.
MMR Achievement
64% MMR achievement by 24 weeks across all efficacy-evaluable patients, with 75% MMR achievement at doses > 320mg QD.
Safety and Tolerability
Encouraging safety and tolerability profile maintained with longer duration of treatment, supporting advanced clinical development.
Response Kinetics
36% DMR achievement rate by 24 weeks at recommended phase 2 doses, showcasing fast response kinetics of TERN-701.
- Unprecedented rates of major molecular response in refractory CML patients.
- Positive response achievements in patient subgroups including those with lack of efficacy on prior treatments.
- High potential for TERN-701 to become a leading therapy option in the treatment of chronic myeloid leukemia.
The positive Phase 1 data for TERN-701 presented at ASH demonstrate its potential as an innovative therapy for CML patients, addressing the need for early, broad, and deep responses with favorable safety profiles. TERN-701 shows promise in becoming a best-in-disease therapy for CML.